Evidence map›Paper›PMID 30862091›Full record

ArticleCancers2019

Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs.

Elisa Conde Moreno, Alejandro Pascual, Daniel Prieto-Cuadra, Val F Laza, Javier Molina-Cerrillo, Miren Edurne Ramos-Muñoz, Esperanza Macarena Rodríguez-Serrano, José Luis Soto, Alfredo Carrato, María Laura García-Bermejo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The important role of miR-1-3p in cancers.Journal of translational medicine · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Elisa Conde MorenoBiomarkers and Therapeutic Targets Group and Core Facility, Ramon y Cajal Research Institute, (IRYCIS), 28034 Madrid, RedinRen, Spain. elisa.condem@gmail.com.
Alejandro PascualPathology Department, Ramon y Cajal Research Institute, University Hospital, 28034 Madrid, Spain. alejandro.pascual@salud.madrid.org.
Daniel Prieto-CuadraSynlabPathology, Pathology Department, Virgen de la Victoria, University Hospital, 29010 Málaga, Spain. dannielpriet@hotmail.com.
Val F LazaMicrobiology Department and Bioinformatics Core Facility, IRYCIS, 28034 Madrid, Spain. valfernandez.vf@gmail.com.
Javier Molina-CerrilloMedical Oncology Department, Ramon y Cajal Research Institute, University Hospital, IRYCIS, 28034 Madrid, Spain. javier.molinace@gmail.com.
Miren Edurne Ramos-MuñozBiomarkers and Therapeutic Targets Group and Core Facility, Ramon y Cajal Research Institute, (IRYCIS), 28034 Madrid, RedinRen, Spain. edurneramosmunoz@gmail.com.
Esperanza Macarena Rodríguez-SerranoBiomarkers and Therapeutic Targets Group and Core Facility, Ramon y Cajal Research Institute, (IRYCIS), 28034 Madrid, RedinRen, Spain. e.makarena@hotmail.es.
José Luis SotoHereditary Cancer Program Valencian Region, Molecular Genetics Laboratory, Elche University Hospital, Elche, 03202 Alicante, Spain. soto_jos@gva.es.
Alfredo CarratoMedical Oncology Department, Ramon y Cajal Research Institute, University Hospital, IRYCIS, Alcala University, 28034 Ciberonc, Spain. acarrato@telefonica.net.
María Laura García-BermejoBiomarkers and Therapeutic Targets Group and Core Facility, Ramon y Cajal Research Institute, (IRYCIS), 28034 Madrid, RedinRen, Spain. garciabermejo@gmail.com.
Carmen Guillén-PonceMedical Oncology Department, Ramon y Cajal Research Institute, University Hospital, IRYCIS, 28034 Madrid, Spain. carmenguillenponce@gmail.com.
Instituto Cajal · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital General Universitario de Elche · ESInstituto Ramón y Cajal de Investigación Sanitaria · ES

Funding

Comunidad de Madrid S2010/BMD-2344Instituto de Investigación sanitaria Ramón y Cajal (IRYCIS) FIBIO EM 003/2010Instituto de Salud Carlos III PI12/01635Instituto de Salud Carlos III PI15/01715Instituto de Salud Carlos III PI15/02101Instituto de Salud Carlos III PS12/00094
6 · The paper itself

Abstract

microRNAs (miRNA) expression in colorectal (CR) primary tumours can facilitate a more precise molecular characterization. We identified and validated a miRNA profile associated with clinical and histopathological features that might be useful for patient stratification. In situ hybridization array using paraffin-embedded biopsies of CR primary tumours were used to screen 1436 miRNAs. 17 miRNAs were selected for validation by quantitative reverse transcription polymerase chain reaction (qRT-PCR) (

Indexed as

biomarkerscolorectal cancermiRNAspatient stratification

Identifiers

PMID30862091
PMCPMC6468580
OpenAlexW2921763806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.